Get the Stockscreener App
14.84
1.59%
0.235
Eton Pharmaceuticals Inc stock is traded at $14.84, with a volume of 18,251.
It is up +1.59% in the last 24 hours and down -9.64% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$14.60
Open:
$14.85
24h Volume:
18,251
Relative Volume:
0.07
Market Cap:
$387.39M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-57.06
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
+1.66%
1M Performance:
-9.64%
6M Performance:
+188.01%
1Y Performance:
+232.57%
1-Day Range:
$14.68
$15.50
1-Week Range:
$12.94
$15.50
52-Week Range:
$3.03
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
14.84 | 387.39M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
159.60 | 71.40B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.01 | 47.36B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 46.03B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.23 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.27 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharma rises on study results for rare disease drug - TradingView
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - GlobeNewswire
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Trading (ETON) With Integrated Risk Controls - Stock Traders Daily
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - GlobeNewswire
How Will Eton's Rare Disease Acquisitions Impact Future Growth? Investor Day Set to Reveal Strategy - StockTitan
Eton Pharmaceuticals Launches Galzin Capsules for Wilson Disease Treatment -March 03, 2025 at 11:48 am EST - Marketscreener.com
Eton Pharmaceuticals launches FDA-approved Wilson disease treatment - Investing.com
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules - GlobeNewswire
Only FDA-Approved Zinc Treatment for Wilson Disease Now AvailableWhat Makes Galzin Different? - StockTitan
60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Anchor Capital Advisors LLC - MarketBeat
(ETON) Trading Report - Stock Traders Daily
Acuitas Investments LLC Has $2.48 Million Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
Insider Buying: Opaleye Management Inc., Eton Pharmaceuticals Inc [ETON] 10% Owner invested 10,000 shares - Knox Daily
What Are You Thinking About Investing In Eton Pharmaceuticals Inc (NASDAQ: ETON) Stock? - Stocks Register
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going - MSN
Learn to Evaluate (ETON) using the Charts - Stock Traders Daily
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 - MSN
FDA extends target action date for Eton's ET-400 - MSN
Eton Pharmaceuticals Receives FDA Extension for NDA for ET-400On February 6, 2025, Eton Pharmaceuticals, Inc. announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUF - Defense World
Eton Pharmaceuticals receives new U.S. patent for ET-600 - MSN
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors - Simply Wall St
Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation -February 07, 2025 at 07:09 am EST - Marketscreener.com
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 - The Manila Times
Major Patent Win: Eton's Game-Changing Liquid Diabetes Drug Gets 20-Year Protection - StockTitan
Eton Pharmaceuticals Says ET-400 FDA Decision Delayed to May -February 06, 2025 at 10:15 am EST - Marketscreener.com
Eton Pharmaceuticals : FDA Extends ET-400 Review to Late May -February 06, 2025 at 08:37 am EST - Marketscreener.com
Eton Pharmaceuticals: FDA Extends ET-400 Review to Late May - MarketWatch
Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28 - TipRanks
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 - GlobeNewswire
Eton's Pediatric Rare Disease Drug Faces 3-Month FDA Review ExtensionRevenue Outlook Unchanged - StockTitan
Baader Bank Aktiengesellschaft Takes $373,000 Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
Biotech Stocks Facing FDA Decision In February 2025 - RTTNews
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 By Investing.com - Investing.com Nigeria
New Strong Buy Stocks for January 28th - Yahoo Finance
Here's What Could Help Eton Pharmaceuticals (ETON) Maintain Its Recent Price Strength - Yahoo Finance
Q2 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst - MarketBeat
Q2 EPS Estimate for Eton Pharmaceuticals Raised by Analyst - Defense World
Eton Pharmaceuticals price target raised to $23 from $18 at Craig-Hallum - Yahoo Finance
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - MSN
HC Wainwright Has Negative Outlook for ETON Q1 Earnings - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Lowered by Analyst - MarketBeat
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):